NHPD Site Licence Requirements: What Canadian Manufacturers and Importers Really Need to Know

One of the more consistent surprises we see from companies entering the Canadian NHP market is the scope of who actually needs a Site Licence. Manufacturers expect it. But importers? Packagers? Companies whose entire role is labelling finished product? All of them are captured under the Natural Health Products Regulations (NHPR), SOR/2003-196 — and operating without the right licence is not a technicality you can quietly fix after the fact.

Health Canada’s Natural and Non-prescription Health Products Directorate (NNHPD — still widely called the NHPD, and we’ll use both interchangeably here) has processed Site Licence applications since the NHPR came into force in 2004. The process has matured considerably, but the deficiency rate for incomplete submissions remains frustratingly high. Most deficiencies aren’t the result of genuine GMP failures. They’re documentation gaps that a systematic pre-submission review would have caught.

Who Needs an NHPD Site Licence — and for Which Activities

Under Section 34 of the NHPR, no person may manufacture, package, label, import, or distribute NHPs for sale in Canada unless they hold a valid Site Licence authorizing those activities at that address. The key word is activities — and it’s specific, not general.

A Site Licence is not a blanket authorization. Each licence lists the particular activities conducted at a particular location. If you manufacture at Site A and import at a bonded warehouse operating as Site B, you need the appropriate activities authorized at each address separately. Auditors check this early, and inconsistencies between your operational reality and your licence scope are a finding waiting to happen.

The five regulated activities under the NHPR are:

• Manufacturing (including synthesis, formulation, and compounding)
• Packaging
• Labelling
• Importing
• Distribution (where the distributor takes title to the product and bears responsibility for NHP compliance)

Testing-only facilities don’t need a Site Licence. But if your third-party analytical lab is a cornerstone of your quality system — running identity testing, potency assays, or contamination screens on your NHP materials — their competency and GMP alignment still factor into your compliance picture during an inspection.

The Six Application Requirements You Can’t Afford to Underestimate

Health Canada uses an online portal for Site Licence applications. Before you submit, six core elements need to be in order.

1. Attestation of GMP Compliance

This is the element that most consistently generates deficiency notices. Health Canada requires evidence that your facility operates in accordance with the Good Manufacturing Practices Guidance Document for Licensed Natural Health Products. For Canadian facilities, this means a GMP attestation signed by your Qualified Person in Charge (QPIC) — the individual formally responsible for GMP compliance at your site.

For foreign facilities, Health Canada may accept a valid GMP certificate issued by a recognized foreign regulatory authority: the US FDA, the European Medicines Agency (EMA), or Australia’s Therapeutic Goods Administration (TGA) are among those recognized. The certificate must cover the specific activities you’re applying to conduct. A pharmaceutical manufacturing certificate won’t carry over to authorize your packaging operation if it runs at a separate address.

2. Description of Activities

Precision matters here. Vague descriptions — “all NHP activities,” “manufacturing and distribution” — get flagged. Reviewers want to understand: Are you formulating finished dosage forms? Repackaging bulk material into consumer units? Conducting in-process water testing? Each activity has GMP implications that the reviewer will evaluate against the evidence you’ve provided. The more specific your description, the easier it is for a reviewer to tick their boxes.

3. Product Type and Dosage Form Information

The application asks which dosage forms and product categories you work with, and this matters because GMP requirements are tiered. Sterile injectables demand environmental monitoring, validated sterilization processes, and water-for-injection systems. Encapsulated herbal powders have entirely different control requirements. A mismatch between your stated product types and your documented GMP controls is an immediate red flag.

4. Qualified Person in Charge (QPIC)

Every Site Licence must designate at least one QPIC who meets the criteria in Section 44 of the NHPR. At minimum, they must hold a post-secondary degree or diploma in a relevant health, science, or technical discipline, plus at least 2 years of relevant experience in manufacturing, quality assurance, or regulatory affairs for health products.

The more important point: the QPIC must be employed at the site. Health Canada has steadily tightened its interpretation of this requirement over the last several years. A consultant engaged on a part-time retainer basis is unlikely to satisfy the requirement. If your designated QPIC spends most of their working hours at a different address, expect scrutiny.

5. Evidence of GMP Practices

The portal doesn’t always require document uploads at initial submission — but don’t mistake that for an invitation to leave your GMP documentation package undeveloped. When Health Canada sends a clarification request (which happens regularly), you’ll have a response window of roughly 30 days. Companies that have a structured submission binder ready respond faster and with fewer errors than those scrambling to produce SOPs under deadline.

6. Contact and Legal Business Information

This sounds straightforward, but errors here — wrong legal entity name, an outdated registered address, mismatched province of incorporation — create downstream problems with certificate issuance, renewal notices, and inspection correspondence. Cross-check your application data against your current corporate registry filings before you submit.

GMP Evidence: The Part That Trips Up Most Applicants

Health Canada’s GMP Guidance for NHPs is organized around 12 chapters covering premises, equipment, personnel, documentation, production controls, quality control, stability testing, sterile product requirements, recall procedures, and more. It’s adapted from the ICH Q7 framework but calibrated for the NHP context. Most applicants struggle with documentation rather than physical facility deficiencies.

Three areas generate the bulk of the deficiency notices we encounter in practice.

Supplier Qualification

Raw material supplier qualification is required under the GMP Guidance, and for botanical ingredients especially, a Certificate of Analysis from the supplier is not sufficient on its own. Your quality system must document your own evaluation: identity verification (ideally by methods referenced in USP, WHO, or equivalent pharmacopoeial monographs), purity testing, and potency testing where applicable.

Heavy metals in botanical raw materials are a particular area of Health Canada scrutiny. The regulatory limits are strict: arsenic ≤ 3 ppm, cadmium ≤ 0.3 ppm, lead ≤ 2 ppm, and mercury ≤ 0.1 ppm per finished product dose. Supplier COAs routinely lack the methodology detail and detection sensitivity needed to satisfy these limits documentarily. Independent third-party testing using ICP-MS is increasingly the expected standard.

Master Formulae and Batch Records

Your Master Formula must capture every raw material with supplier qualification evidence attached, every process step with in-process controls defined, and finished product specifications with testing acceptance criteria. Batch records must demonstrate, lot by lot, that each batch was manufactured and tested in conformance with the Master Formula. Gaps here don’t just create a licensing problem — they create the evidentiary foundation for a recall if something goes wrong post-market.

Change Control

Many facilities pass their initial inspection cleanly but fall out of compliance later because they didn’t manage post-licence changes. Under the NHPR, changes that affect the activities, product types, or personnel on your licence require either a notification (for minor changes) or a formal amendment submission (for significant ones) to the NNHPD. Adding a new contract manufacturer, relocating your warehouse to a new address, or replacing your QPIC all have regulatory implications. A robust change control SOP that explicitly includes “does this trigger a site licence amendment?” as a mandatory review step is worth building early.

How to Structure Your Submission for First-Pass Approval

Following a disciplined pre-submission process consistently improves first-pass approval rates.

1. Map your activities before you write anything. Draw a simple process flowchart from raw material receipt through finished product release and distribution. Every operational box in that diagram is a potential licensed activity.

2. Audit your GMP documentation against all 12 chapters. Use Health Canada’s own GMP Guidance as your checklist. For each chapter, note what you have, what’s missing, and what requires remediation before you’re ready to submit.

3. Confirm your QPIC meets Section 44. Review their CV against the regulatory criteria carefully. If there’s any ambiguity around their educational background or years of experience, resolve it before the application — not in response to a deficiency notice.

4. Prepare your facility description with specificity. Reviewers look for consistency between your narrative facility description, your stated activities, and your GMP evidence package. An encapsulation line mentioned in your SOPs but absent from your equipment list creates an inconsistency that invites questions.

5. Build a submission binder. Even if uploads aren’t required at submission, organize all supporting documents — SOPs, facility diagrams, equipment qualification records, supplier qualification files — into a structured reference package. When a clarification request arrives, having this ready saves significant time.

6. Submit and track your application status. The NNHPD publishes expected review timelines. Straightforward initial applications have historically resolved within 30 to 90 days; complex applications or those triggering facility inspection take longer. Know the expected timeline so you can follow up appropriately rather than chasing the review unnecessarily.

After Your Licence Is Issued: Renewal and Ongoing Compliance

A Site Licence is valid for one year from issuance and requires annual renewal. Renewal is not automatic — each cycle requires a renewal application with an updated GMP attestation, confirmation or correction of all listed activities and product types, and any changes to QPIC designations or facility information.

Health Canada conducts both announced and unannounced facility inspections. Inspection frequency correlates with product risk profile, compliance history, and adverse event reporting patterns. Facilities manufacturing sterile products or those with documented quality issues see inspections more frequently. An Establishment Inspection Report with corrective action requirements is not the end of the road — but repeated or serious GMP failures can result in licence suspension, which effectively halts your ability to sell any NHP in Canada.

The administrative machinery of NHP licensing rewards genuine preparation. The companies that treat their Site Licence application as a documentation exercise to obtain a certificate tend to encounter problems at renewal, at inspection, or when a product complaint escalates into something more serious. The companies that treat the application process as a real GMP readiness exercise build quality systems that hold up — and that’s an operational advantage, not just a regulatory checkbox.

If you’re preparing a first-time application or managing a renewal with significant changes to your operations, a structured gap analysis against Health Canada’s GMP Guidance before you submit is time well invested.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance Contact us

Related from our network

• ISO 17025-Accredited NHP and Supplement Testing Services — Qalitex Laboratories provides accredited heavy metal, identity, and potency testing to support your NHP supplier qualification program and GMP documentation requirements.
• EU Cosmetics and Supplement Regulatory Compliance for European Market Entry — Care Europe helps brands build parallel regulatory strategies for EU and Canadian market access, covering dossier preparation and GMP alignment across jurisdictions.